- Lobbying
- Lobbying by Titan Pharmaceuticals, Inc.
Lobbying Relationship
Bills mentioned
S.2456: CARA 2.0 Act of 2018
Sponsor: Rob Portman (R-Ohio)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Michael Tomberlin | Chief of Staff, Rep. Chip Cravaack, Chief of Staff, Rep. Louie Gohmert Chief of Staff, Rep. Chip Cravaack, Chief of Staff, REp. Louie Gohmert |
Kent Hance | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Pharmacy
Medical
Medicare
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Pharmacy
Medical
Medicare
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Pharmacy
Medical
Medicare
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Pharmacy
Medical
Medicare
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Pharmacy
Medical
Medicare
Registration
Issue(s) they said they’d lobby about: Medicare/Medicaid drug coverage, opioid addiction policy, S.2456 The CARA 2.0 Act of 2018..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate